BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS)
- Reduced disease severity: After two years of BIMZELX®▼ (bimekizumab) treatment, 53.1% (237/446) of patients had mild disease compared to 0.0% at baseline
- Sustained disease control: At two years, 4% (372/446) of patients with hidradenitis suppurativa (HS) remained flare-free, while 86.9% (265/305) of HiSCR75* responders to bimekizumab at 48 weeks maintained this response
- Unique dual inhibition: BIMZELX® is the first and only approved medicine designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F)
Brussels (Belgium), February 12, 2025 – 07:00 (CET) – UCB, a global biopharmaceutical company, today announced long-term data from the BE HEARD^ trials for BIMZELX®▼ (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, building on the established efficacy profile of bimekizumab in HS, showcase that its unique dual inhibition offers a durable treatment option for this challenging, chronic skin condition.1,2,3,4,5
“For people living with HS, draining tunnels associated with moderate and severe disease can be incredibly distressing and painful – often derailing daily life,” said Professor Christos C. Zouboulis, President of the European Hidradenitis Suppurativa Foundation (EHSF) e.V., Director of the Departments of Dermatology, Venereology, Allergology and Immunology, Städtisches Klinikum Dessau, and Founding Professor of Dermatology and Venereology at the Brandenburg Medical School, Germany. “These new, specific two-year data demonstrate bimekizumab’s ability to provide sustained disease control, meaning a shift towards mild disease characterized by the absence of draining tunnels, offering hope for long-term disease management and reduced burden for HS patients.”
Among patients who achieved response to bimekizumab at one year, over 85.0% maintained response across a range of endpoints to two years (percentage responders at Week 48 through Week 96: 90.0% (332/369) maintained HiSCR50; 86.9% (265/305) maintained HiSCR75; 86.0% (234/272) maintained DLQI MCID).1 Improvements in disease severity, as measured by IHS4π (a validated clinician-rated tool), were demonstrated with the majority of patients shifting over two years from severe to mild and moderate disease (baseline to two-year data: mild: 0.0% to 53.1% (237/446); moderate:12.6% (70/556) to 26.5% (118/446); severe: 87.4% (486/556) to 20.4% (91/446).2 The mean (SD) draining tunnel count also decreased over two years.2 Additionally, patients reported that gradual improvement to no/mild severity of symptoms translated to improved health-related quality of life over two years.3 This highlights the impact of bimekizumab in providing durable control of symptoms which contribute to the profound negative effects of HS on patients’ quality of life.3,6
“As the first presentation of bimekizumab data this year, we are thrilled it demonstrates the durability of response in HS treatment,” said Fiona du Monceau, Executive Vice President, Head of Patient Evidence, UCB. “Sustained flare control, maintenance of response and improvement across multiple measures of disease severity through two years show how bimekizumab can transform outcomes for people living with HS. These data confirm our commitment to improving the lives of those living with HS, now and into the future.”
Abstracts will be presented as two posters and three oral presentations today, at the 14th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) in Vilnius, Lithuania.1,2,3,4,5
^Further results from BE HEARD EXT evaluating the efficacy and safety profile of bimekizumab will be presented later this year.
*HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess and inflammatory nodule or draining tunnel count.7
πIHS4 is a validated clinician-rated tool that assigns different weights to the number of inflammatory nodules, abscesses and draining tunnels (DTs).2 The presence of a draining tunnel is sufficient to classify an HS patient as at least moderate.8
